Results 31 to 40 of about 6,429 (163)

Tumor Tropism of DNA Viruses for Oncolytic Virotherapy

Viruses, 2023
Oncolytic viruses (OVs) have emerged as one of the most promising cancer immunotherapy agents that selectively target and kill cancer cells while sparing normal cells. OVs are from diverse families of viruses and can possess either a DNA or an RNA genome.
Junior A. Enow, Hummad I. Sheikh, Masmudur M. Rahman   +2 more
doaj   +1 more source

Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus

Molecular Therapy, 2009
Hypoxia contributes to the resistance of tumors to conventional therapies. We hypothesized that their replication in hypoxic environments like brain or oral mucosa would make oncolytic herpes simplex viruses (HSVs) such as G207 (which has undergone clinical trials) replicate to a greater extent in hypoxic tumors like glioblastoma.
Aghi, Manish K, Liu, Ta-Chiang, Rabkin, Samuel, Martuza, Robert L   +3 more
openaire   +2 more sources

Adenovirus as a Vector and Oncolytic Virus

Current Issues in Molecular Biology, 2023
Adenoviral vectors, both oncolytic viruses and gene delivery vectors, are among the earliest approved and commercialised vectors for gene therapy. Adenoviruses have high cytotoxicity and immunogenicity. Therefore, lentiviruses or adeno-associated viruses
Wataru Matsunaga, Akinobu Gotoh
doaj   +1 more source

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

OncoImmunology, 2018
Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi   +14 more
doaj   +1 more source

Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1

Molecular Therapy: Oncolytics, 2019
The efficacy of immune checkpoint blockade therapy against immunologically “cold” tumors can be enhanced by applying the checkpoint inhibitors in combination with oncolytic viruses.
Yujie Zhu, Xiao Hu, Lin Feng, Zhenrong Yang, Lulin Zhou, Xinchun Duan, Shujun Cheng, Wen Zhang, Binlei Liu, Kaitai Zhang   +9 more
doaj   +1 more source

Sequence of a fusogenic herpes simplex virus, RH2, for oncolytic virotherapy

Journal of General Virology, 2013
RH2 is a novel oncolytic herpes simplex virus type 1 (HSV-1) produced by simultaneous infection with neurovirulent γ134.5 gene-deficient HSV-1 R849 derived from strain F and the spontaneously occurring, fusogenic HSV-1 HF in cell culture. The genome of RH2 was studied using Genome Sequencer FLX.
Gen, Takahashi, Noritoshi, Meshii, Masakazu, Hamada, Soichi, Iwai, Yoshiaki, Yura   +4 more
openaire   +2 more sources

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy [PDF]

Frontiers in Oncology, 2017
Vaccines and immunotherapeutic approaches to cancers with the advent of immune checkpoint inhibitors and chimeric antigen receptor-modified T cells have recently demonstrated preclinical success and entered clinical trials. Despite advances in these approaches and combinatorial therapeutic regimens, depending on the nature of the cancer and the immune ...
Jie Yin, Jie Yin, James M. Markert, James M. Markert, James M. Markert, Jianmei W. Leavenworth, Jianmei W. Leavenworth   +6 more
openaire   +3 more sources

Triple-armed oncolytic HSV enhances antitumor immunity by remodeling the tumor microenvironment in subcutaneous murine CRC

iScience
Summary: Colorectal cancer (CRC) is characterized by therapeutic resistance and an immunosuppressive tumor microenvironment (TME). In the present study, five oncolytic herpes simplex virus type 1 (oHSV) variants were constructed based on the herpes ...
Lei Zhang, Kunpeng Zheng, Wu Tong, Fengnian Chen, Yanbing Zhu, Shuxin Han, Zhenghai Ma   +6 more
doaj   +1 more source

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002

Molecular Therapy: Oncolytics, 2017
Despite advances in conventional chemotherapy, surgical techniques, and radiation, outcomes for patients with relapsed, refractory, or metastatic soft tissue sarcomas are dismal. Survivors often suffer from lasting morbidity from current treatments.
Eric K. Ring, Rong Li, Blake P. Moore, Li Nan, Virginia M. Kelly, Xiaosi Han, Elizabeth A. Beierle, James M. Markert, Jianmei W. Leavenworth, G. Yancey Gillespie, Gregory K. Friedman   +10 more
doaj   +1 more source

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta [PDF]

Cancer Cell International, 2014
Oncolytic herpes simplex virus (HSV) can replicate in and kill cancer cells while sparing the adjacent normal tissue. Hepatocellular carcinoma (HCC) is amongst the most common and lethal cancers, especially in Third World countries. In this study, the cytotoxicity of a third-generation oncolytic HSV, G47Δ, was investigated in different human HCC cell ...
Wang, Jiani, Xu, Lihua, Zeng, Weigen, Hu, Pan, Zeng, Musheng, Liu, Renbin, Rabkin, Samuel   +6 more
openaire   +4 more sources